FOLH1 and nervous system disorder: Small-molecule GCPII inhibitors containing glutamate-mimetics have been used as a treatment for neurological disorders in preclinical models [15,64,66,69,70,71,72,73,74,75,76,77]; however, their therapeutic potential in the clinic has been hampered, in part due to poor oral bioavailability and negligible brain penetration.